BridgeBio Pharma, Inc. Forecasted to Earn FY2023 Earnings of ($3.80) Per Share (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIOFree Report) – Analysts at Leerink Partnrs boosted their FY2023 EPS estimates for shares of BridgeBio Pharma in a research report issued on Wednesday, February 7th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($3.80) per share for the year, up from their prior forecast of ($3.84). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.93) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q4 2023 earnings at ($0.86) EPS, Q1 2024 earnings at ($0.28) EPS, Q2 2024 earnings at ($0.93) EPS, Q3 2024 earnings at ($0.97) EPS, Q4 2024 earnings at ($1.00) EPS and FY2024 earnings at ($3.26) EPS.

BBIO has been the topic of several other reports. Wells Fargo & Company started coverage on shares of BridgeBio Pharma in a research note on Friday, December 8th. They issued an “overweight” rating and a $58.00 price objective on the stock. Citigroup started coverage on shares of BridgeBio Pharma in a research note on Tuesday, November 7th. They issued a “buy” rating and a $42.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price objective on shares of BridgeBio Pharma in a research note on Monday, January 22nd. HC Wainwright boosted their price objective on shares of BridgeBio Pharma from $22.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, January 29th. Finally, BMO Capital Markets began coverage on shares of BridgeBio Pharma in a research report on Wednesday, January 31st. They set a “market perform” rating and a $37.00 target price on the stock. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

View Our Latest Report on BBIO

BridgeBio Pharma Stock Performance

Shares of BBIO opened at $35.65 on Monday. The stock has a market capitalization of $6.20 billion, a P/E ratio of -9.14 and a beta of 1.07. The company’s fifty day moving average is $37.06 and its two-hundred day moving average is $31.45. BridgeBio Pharma has a 1 year low of $10.57 and a 1 year high of $44.32.

Institutional Trading of BridgeBio Pharma

Large investors have recently bought and sold shares of the company. Assetmark Inc. purchased a new position in shares of BridgeBio Pharma during the 3rd quarter valued at approximately $53,000. Clear Street Markets LLC bought a new position in BridgeBio Pharma during the first quarter worth $33,000. Covestor Ltd lifted its stake in BridgeBio Pharma by 22,905.6% during the second quarter. Covestor Ltd now owns 4,141 shares of the company’s stock worth $71,000 after purchasing an additional 4,123 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in BridgeBio Pharma by 98.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,171 shares of the company’s stock worth $110,000 after purchasing an additional 2,067 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in BridgeBio Pharma by 500.0% in the first quarter. Quantbot Technologies LP now owns 4,200 shares of the company’s stock worth $42,000 after buying an additional 3,500 shares during the period. Institutional investors and hedge funds own 90.85% of the company’s stock.

Insider Buying and Selling

In related news, Director Frank Mccormick sold 100,000 shares of the business’s stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $42.06, for a total value of $4,206,000.00. Following the sale, the director now directly owns 627,689 shares in the company, valued at approximately $26,400,599.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other BridgeBio Pharma news, Director Randal W. Scott sold 2,000 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $40.00, for a total value of $80,000.00. Following the transaction, the director now directly owns 9,000 shares in the company, valued at approximately $360,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Frank Mccormick sold 100,000 shares of the company’s stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $42.06, for a total transaction of $4,206,000.00. Following the transaction, the director now directly owns 627,689 shares of the company’s stock, valued at approximately $26,400,599.34. The disclosure for this sale can be found here. Insiders have sold 104,915 shares of company stock worth $4,396,683 in the last three months. Corporate insiders own 28.52% of the company’s stock.

BridgeBio Pharma Company Profile

(Get Free Report)

BridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

See Also

Earnings History and Estimates for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.